From: High prevalence of ESBL-producing E. coli phylogroup B2 clinical isolates in northeastern Thailand
Cephalosporin resistant E. coli (n = 202) | Resistance gene profile | Phylogroup | Total | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
A | B1 | B2 | C | D | E | F | Clade I | NT | |||
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
ESBL-producing (n = 195) | blaTEM | 2 (10.5) | 3 (15.8) | 7 (36.8) | 1 (5.3) | 2 (10.5) | 1 (5.3) | 1 (5.3) | 2 (10.5) | 19 | |
blaTEM+blaCIT | 5 (83.3) | 1 (16.7) | 6 | ||||||||
blaTEM+blaDHA | 1 (100) | 1 | |||||||||
blaTEM+ blaCTX−M (unknown group) | 3 (20) | 3 (20) | 2 (13.3) | 3 (20) | 3 (20) | 1 (6.7) | 15 | ||||
blaTEM+ blaCTX−M (unknown group) + blaCIT | 1 (100) | 1 | |||||||||
blaTEM+blaCTX−M−1 | 10 (19.2) | 2 (3.9) | 22 (42.3) | 3 (5.8) | 7 (13.5) | 3 (5.8) | 1 (1.9) | 1 (1.9) | 3 (5.8) | 52 | |
blaTEM+blaCTX−M−9 | 22 (75.9) | 4 (13.8) | 3 (10.3) | 29 | |||||||
blaTEM+blaCTX−M−9+blaDHA | 1 (10) | 6 (60) | 1 (10) | 2 (20) | 10 | ||||||
blaTEM+blaCTX−M−1+blaCTX−M−9 | 5 (26.3) | 1 (5.3) | 11 (57.9) | 2 (10.5) | 19 | ||||||
blaTEM+blaCTX−M−1+blaCTX−M−9+blaDHA | 1 (100) | 1 | |||||||||
blaCTX−M (unknown group) | 1 (100) | 1 | |||||||||
blaCTX−M−1 | 10 (52.6) | 2 (10.5) | 3 (15.8) | 2 (10.5) | 1 (5.3) | 1 (5.3) | 19 | ||||
blaCTX−M−9 | 5 (83.3) | 1 (16.7) | 6 | ||||||||
blaCTX−M−1+blaCTX−M−9 | 5 (100) | 5 | |||||||||
blaTEM+ blaCTX−M (unknown group) + blaSHV | 1 (100) | 1 | |||||||||
blaTEM+blaCTX−M−1+blaSHV | 3 (100) | 3 | |||||||||
blaTEM+blaCTX−M−9+blaSHV | 1(100) | 1 | |||||||||
Not detected | 1 (16.7) | 4 (66.7) | 1 (16.7) | 6 | |||||||
ESBL-non-producing (n = 7) | blaTEM+blaCIT | 1 (11.1) | 1 (11.1) | 2 (22.2) | 4 | ||||||
blaTEM+blaDHA | 1 (100) | 1 | |||||||||
blaCIT | 1 (50) | 1 (50) | 2 | ||||||||
Total | 17 | 13 | 85 | 20 | 21 | 8 | 22 | 3 | 13 | 202 |